Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Class I recall for Colleague pumps

This article was originally published in The Silver Sheet

Executive Summary

A recent recall by Baxter was designated Class I by FDA July 18. The firm recalled 4,500 upgraded versions of its triple-channel Colleague infusion pumps in June after it received reports of 16 serious injuries resulting from an interruption of medication that occurred when pumps distributed to hospitals between May 14 and June 20 experienced a "buffer overflow." Baxter says it has identified a fix for the problem, which relates to how the product handles a combination of "intensive" commands, but is waiting on FDA to validate its corrective action before it resumes upgrading its 75,000-unit triple-channel installed base. Colleague devices experienced multiple Class I recalls in 2005 and 2006 and a seizure by FDA in October 2005 ("The Silver Sheet" October 2005)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel